Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 13, 2017 11:53 ET | Source: INNATE PHARMA

Issuance by Innate Pharma of 3,343,748 ordinary shares to Novo Nordisk A/S in consideration for rights in anti-C5aR

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Issuance by INNATE PHARMA of 3,343,748...
July 13, 2017 11:53 ET | Source: INNATE PHARMA

Innate Pharma: Émission de 3 343 748 actions ordinaires au bénéfice de Novo Nordisk A/S en rémunération des droits sur l'anti-C5aR

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} ÉMISSION PAR INNATE PHARMA DE 3 343 748...
June 26, 2017 01:00 ET | Source: INNATE PHARMA

INNATE PHARMA : Résultats de l'Assemblée générale et évolutions au sein de la gouvernance et du management de la société

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Résultats de l'Assemblée générale et...
June 26, 2017 01:00 ET | Source: INNATE PHARMA

INNATE PHARMA : Results of Annual General Meeting and changes to Innate Pharma's governance and management team

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Results of Annual General Meeting and...
June 15, 2017 01:00 ET | Source: INNATE PHARMA

INNATE PHARMA : Résultats d'escalade de dose d'IPH4102 : Profil de tolérance et activité clinique prometteurs

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} rÉsultats d'escalade de dose...
June 15, 2017 01:00 ET | Source: INNATE PHARMA

INNATE PHARMA : Dose-escalation data show favorable safety profile and promising clinical activity for IPH4102

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} DOSE-ESCALATION DATA SHOW favorable...
June 02, 2017 16:26 ET | Source: INNATE PHARMA

Innate Pharma acquires anti-C5aR, a first-in-class clinical-stage antibody, from Novo Nordisk A/S

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} INNATE PHARMA STRENGTHENS ITS...
June 02, 2017 16:26 ET | Source: INNATE PHARMA

Innate Pharma acquiert l'anti-C5aR, un anticorps en Phase clinique, auprès de Novo Nordisk A/S

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} INNATE PHARMA RENFORCE SON...
May 23, 2017 01:00 ET | Source: INNATE PHARMA

Innate Pharma annonce la tenue de son Assemblée Générale Annuelle le 23 juin 2017 à Marseille

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} INNATE PHARMA ANNONCE LA TENUE DE...
May 23, 2017 01:00 ET | Source: INNATE PHARMA

Innate Pharma to hold its Annual General Meeting of shareholders on June 23, 2017

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} INNATE PHARMA TO HOLD ITS ANNUAL...